CASE STUDIES & RESEARCH

Our case studies and publications provide an inside look at how our products and solutions have been used to meet diverse hospital needs.

UVC simulated EPA testing protocol for Hospital Grade Disinfection compared to Whole Room HOCL fogging technology

Healthcare Associated Infections (HAIs) are an enormous problem for patients and acute healthcare facilities. To reduce HAIs, many hospitals are employing innovative technology to supplement manual cleaning practices in their quest to combat pathogens in their facility. Whole room fogging technology and UVC light technology are two technologies being used in today’s healthcare environments.

Nimbus Disinfection Protocol Efficacy Validated by Two Arizona Hospitals for Pathogen Reduction

Healthcare Associated Infections (HAIs) are a huge problem for patients and acute healthcare facilities. The impact of HAIs is detrimental to patient outcomes and increases the cost of provider care. In hospitals alone, the Centers for Disease Control and Prevention (CDC) estimate HAIs account for 1.7 million infections and more than 98,000 deaths each year.1 Approximately $45 billion in direct hospital costs are associated annually for the treatment of HAIs.2 Hospital environment, health care staff, visitors and patient medical conditions are contributing factors to the development of HAIs.

Independent Testing: Effectiveness of the Nevoa Disinfection System

Nevoa® is a healthcare innovation company dedicated to reducing the impact of hospital acquired infections (HAIs) through better disinfection technology. 

 

Nevoa saw a need to reduce human error and cross-contamination common to manual disinfection protocols. Nevoa developed a system consisting of a proprietary hypochlorous acid (HOCl) solution called Nevoa Microburst SolutionTM and an automated robot called NimbusTM. The patented Nimbus device atomizes (fogs) the disinfectant for whole-room disinfection including 100% of a room’s surfaces as well as room air. This system is the only US Environmental Protection Agency (EPA) registered disinfectant approved for fogging HOCl in healthcare environments. Rigorous testing has been conducted through independent laboratories to provide the necessary validation studies for EPA registration. Additional studies have also been conducted to demonstrate efficacy against several specific pathogens of interest.

Impact of a Whole-Room Atomizing Disinfection System on Healthcare Surface Contamination, Pathogen Transfer, and Labor Efficiency

Assess the effectiveness of a whole-room, no-touch disinfection system in conjunction with manual cleaning protocols in reducing bacterial contamination on healthcare surfaces.

The role of the hospital bed in hospital-onset Clostridioides difficile: A retrospective study with mediation analysis

In this retrospective cohort study, we used a real-time location system to track the movement of hospital beds in 2 academic hospitals to determine whether residing in a hospital bed that previously held an occupant with Clostridioides difficile increases the risk of hospital-onset C. difficile infection (HO-CDI).

Fogging HOCl for Patient Room Disinfection Brings Added Benefit of Floor Pathogen Reduction

Prevention of healthcare associated infections (HAIs) remains a priority for hospitals and healthcare facilities. Every year nearly 1.7 million hospitalized patients acquire an HAI while being treated for another health issue, and more than 98,000 patients die due to these infections.

The Impact of Handheld Hypochlorous Acid on Procedural Room Humidity Levels

Controlling proper humidity levels in the operating room is essential for infection prevention and patient safety. CMS and AORN guidelines recommend that humidity levels in surgical suite procedure rooms should be maintained between 20% and 60%.

Reducing Hospital-Onset C. Difficile Infections in an Oncology Unit with Advanced Disinfection Using Hypochlorous Acid

Healthcare associated infections (HAIs) are an enormous problem in hospitals, and contribute to the morbidity and mortality of patients. Oncology and similar high-risk patients are extremely susceptible to the development of HAIs due to their compromised immune systems.

Subscribe to Newsletter

Enter your email address to register 

to our newsletter subscription!